Touchlight Genetics
Hampton
About Touchlight Genetics
Touchlight Genetics develops a DNA production platform designed for the development of DNA vaccines for oncology and infectious diseases. Founded in 2007, Touchlight brings together a highly talented scientific and drug development team supported by an experienced board. Founder and CEO Jonny Ohlson has assembled a dynamic management team, including Clive Dix, Non-Executive Chairman, and John Tite, Executive Head of Research (formerly founding CEO of Bicycle Therapeutics), with substantial experience in growing life science companies and particularly in DNA vaccines. Touchlight is supported by a group of Non-Executive Directors, who bring a wealth of healthcare and entrepreneurial experience. Led by experienced drug pharmaceutical scientists Neil Porter and Jill Makin, Touchlight’s scientific team- some of the brightest talents in the UK industry- has successfully established and patented the proTLx™ synthetic DNA platform as well as successfully establishing the first therapeutic proof-of-principle through collaboration with leading academic partners. The company has established strong collaborative links with academic laboratories worldwide including Imperial College London, Southampton University, Queen’s University Belfast and the University of Pennsylvania in the US.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $1K – $10K
- Total funding: $130.4M
- Last round: Grant (Nov 2022)
- Website: touchlight.com
- Phone: +44 (0)20 8481 9200
Industries & Categories
Biopharma, Biotechnology, Health Care, Medical, Oncology
Social Profiles
Canonical: https://fsome.com/organization/touchlight-genetics-33589 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.